title: Benefits of pazopanib over sunitinib for renal cell carcinoma.
authors: Michael
authors: M
authors: Granovetter
mesh_terms: D006801:Humans; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D007191:Indazoles; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D061214:Patient Safety / Q000706:statistics & numerical data; D011379:Prognosis; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D012680:Sensitivity and Specificity; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D000077210:Sunitinib; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D007211:Indoles; C516667:pazopanib; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000077210:Sunitinib